Objective
The objective of this project is to create the first technology capable of measuring the body’s insulin production in real time. Achieving this goal would address a major gap in diabetes care and research by providing direct insight into how well the pancreas is functioning, information that is simply not available via current technologies.
When the pancreas releases insulin, it simultaneously releases a molecule called C-peptide. Because C-peptide is produced only when the body makes its own insulin and, unlike insulin itself, is not rapidly cleared by the liver, it serves as a reliable indicator of recent pancreatic insulin production. Today, however, C-peptide can only be measured through blood draws and laboratory tests, which provide infrequent and delayed results. As a result, clinicians and researchers lack the ability to track rapid changes in insulin secretion, detect early loss of pancreatic function, or easily evaluate therapies designed to protect or restore insulin-producing cells.
The objective of this work is to overcome these limitations by developing a sensor that can measure C-peptide in a manner analogous to how the “continuous glucose monitor” tracks blood sugar: autonomously, and in real time. To do this, we will adapt a proven sensing technology that uses short strands of DNA, called aptamers, that recognize specific molecules in the body. The aptamers are engineered to change shape when they bind to their target, allowing binding events to be converted directly into an electrical signal that can be measured continuously. To achieve this goal, our project focuses on three key outcomes. First, we will create new aptamers that tightly, specifically, and rapidly bind C-peptide. Second, we will integrate these into miniature, “microneedle” sensors capable of operating reliably in the body in blood and tissue fluids. Third, we will test and validate these sensors in an animal model to confirm that they accurately track C-peptide levels over time.
By the end of this project, our objective is to deliver a validated sensor capable of providing real-time information about endogenous insulin secretion. This capability would enable earlier detection of declining pancreatic function, support more precise and personalized insulin therapy, and accelerate the development of treatments aimed at preserving or restoring insulin production. More broadly, achieving this objective would establish a new paradigm for monitoring protein biomarkers in the body, opening the door to improved diagnosis and management of many chronic diseases beyond diabetes.
Background Rationale
Diabetes is a complex disease that develops when the body can no longer produce enough insulin or use it effectively. While current technologies allow people with diabetes to track blood glucose levels continuously, glucose alone does not reveal how well the pancreas, which is the organ responsible for making insulin, is functioning.
A molecule called C-peptide provides a unique window into pancreatic function and dysfunction. Every time the pancreas releases a molecule of insulin, it releases a molecule of C-peptide. Unlike insulin, however, the concentration of C-peptide in the body is not affected by the administration of exogenous insulin as a part of diabetes management and it is not rapidly cleared by the liver, attributes make it both a reliable and a more convenient indicator of the body’s own insulin production. Because of this, measurements of C-peptide can help distinguish between different forms of diabetes, guide treatment decisions, and evaluate therapies aimed at preserving or restoring insulin-producing cells. However, despite its potential, C-peptide is currently measured only through occasional blood draws and laboratory tests, offering limited and delayed insights into the progression and treatment of diabetes. Against this background, a technology supporting the continuous, real-time monitoring of C-peptide (i.e., a technology analogous to the continuous glucose monitor, but aimed at this marker of insulin production) would allow clinicians to detect early loss of pancreatic function, track recovery following treatment, and personalize insulin dosing based on a patient’s real physiological needs. Such a capability would represent a major advance in diabetes care and research.
Developing a sensor that can continuously measure protein biomarkers such as C-peptide inside the body has proven extremely challenging. Most laboratory tests rely on antibodies to recognize specific proteins. While antibodies are highly selective, they do not naturally produce a signal when they bind their target. Sensor technologies therefore attempt to detect indirect changes caused by binding, such as changes in mass or electrical properties at a surface. In complex bodily fluids, however, many non-target proteins stick to sensor surfaces, producing false signals that overwhelm true measurements. These effects have prevented antibody-based sensors from operating reliably outside the laboratory, especially over extended periods.
To address this challenge, researchers have developed an alternative approach based on aptamers, which are short, synthetic strands of DNA that can be designed to bind specific targets. Unlike antibodies, aptamers can be engineered to change shape when they bind their target. This, in turn, can be directly converted into a measurable electrical signal, enabling continuous, real-time measurements. To date, we have already used this strategy to measure a wide range of drugs, metabolites, and proteins directly in living animals and, more recently, in human subjects. The necessary sensors are small, require no added reagents, and can be integrated into easily wearable devices. However, because suitable aptamers have not been available, this powerful technology has not yet been applied to the measurement of C-peptide.
The rationale for this project is that developing C-peptide-specific aptamers and integrating them into this established sensing platform will overcome a long-standing barrier in diabetes monitoring. By enabling real-time measurement of endogenous insulin secretion, this work has the potential to fundamentally improve how diabetes is understood, treated, and managed.
Description of Project
Diabetes, which affects hundreds of millions of people worldwide, arises when the body cannot produce enough insulin or cannot use it effectively. And while blood glucose measurements guide its day-to-day treatment, they do not directly reveal how much insulin a person’s pancreas is producing. This limits our ability to detect early loss or dysfunction of insulin-producing cells, to tailor insulin dosing precisely, and to evaluate therapies designed to restore pancreatic function. An ability to measure C-peptide, which is a protein released into the bloodstream in equal amounts with insulin, would provide a powerful solution to this problem. C-peptide remains in circulation longer than insulin, is not confounded by the administration of exogenous insulin, making it a specific marker of endogenous insulin production, and is not “first pass cleared” by the liver. Together, these attributes render C-peptide not only easier top measure than insulin, but also a more direct measure of -cell insulin production. Today, however, C-peptide can only be measured using blood draws and laboratory tests, providing just rare, delayed snapshots of pancreatic health and not the continuous, real-time picture that would be of greatest clinical value.
Our focus is on the development of a technology that can measure C-peptide with the same ease, convenience, timeliness and duration as continuous glucose monitors measure blood sugar. Such a capability would transform diabetes care by improving the personalization of insulin dosing, earlier detection of declining pancreatic function, and more precise monitoring of treatments intended to preserve or restore insulin production. The challenge in achieving this is that the continuous measurement of peptides in the body has proven extremely difficult. Our approach to generalized, including protein, molecular monitoring uses a class of molecular recognition elements called aptamers, which are short strands of DNA that can be engineered to bind specific targets with high affinity, and can be designed to physically change shape when they bind their target. We exploit these properties in a technology known as electrochemical aptamer-based (EAB) sensors. In these, aptamers are attached to microneedle electrodes and labeled with an electroactive “reporter.” When the aptamer binds its target, its shape change alters the flow of electrons, generating an easily measurable signal that can be recorded continuously, without the need for added chemicals or user intervention.
Over the past decade, our team and others have shown that EAB sensors can measure a wide range of drugs, metabolites, and proteins in living animals—and, more recently, in human subjects—at time resolutions of seconds and for durations of at least a week. These sensors can be incorporated into small, wearable devices attached to the skin via adhesive patches. In this project, we will extend this proven technology to the measurement of C-peptide. To do so, we will first develop new aptamers that bind C-peptide with high specificity and rapid response times. We will then integrate these into EAB sensors and rigorously test their performance on the benchtop in blood and then in laboratory animals. Ultimately, in collaboration with an industry partner, we will adapt the sensors to a wearable format, laying the groundwork for future clinical use.
If successful, this work will establish the first technology capable of performing the real-time, long-term monitoring of endogenous insulin secretion, an advance that would open new possibilities for personalized diabetes care and provide new advances in our understanding of pancreatic health.
Anticipated Outcome
The anticipated outcome of this project is the creation of device able to measure the body’s own insulin production continuously and in real time by measuring C-peptide, a reliable marker of endogenous insulin secretion, an advance that would produce both immediate scientific advances and long-term clinical benefits for people living with diabetes. Specifically, by the end of the proposed research project, we expect to deliver a validated sensor that can accurately and continuously track C-peptide levels in the body. This sensor will be minimally invasive, require no user intervention, and operate reliably in complex environments such tissue fluid in a fashion akin to current continuous glucose monitors. Importantly, its performance will be rigorously tested and confirmed in an animal model, with results benchmarked against established laboratory-based measurements. These studies will establish key performance characteristics, including sensitivity, accuracy, and the ability to follow rapid changes in insulin secretion over time. Finally, through collaboration with an industry partner experienced in wearable sensor technology, this project is expected to produce a clear path toward clinical translation, with the long-term goal of improving disease monitoring, personalizing treatment, and enabling more proactive, data-driven healthcare.
Relevance to T1D
Type 1 diabetes is an autoimmune disease in which the body’s immune system attacks and destroys the insulin-producing cells of the pancreas. As a result, people with Type 1 diabetes must rely on injected insulin to survive. Although advances in glucose monitoring and insulin delivery have greatly improved diabetes care, existing technologies provide little direct information about the health or activity of the remaining insulin-producing cells, leaving an important “clinical knowledge gap.” C-peptide offers a unique and powerful way to address this gap. When the pancreas produces insulin, it releases an equal amount of C-peptide into the bloodstream. Because injected insulin does not contain C-peptide, measuring C-peptide provides a direct measure of the body’s own insulin production even in patients using exogenous insulin. However, today’s C-peptide tests rely on infrequent blood draws, laboratory analysis, and skilled personnel, making it difficult to detect small changes or short-term fluctuations in insulin production.
The technology proposed in this project aims to change that by enabling continuous, real-time measurement of C-peptide. For people with Type 1 diabetes, such a capability could transform both clinical care and research. Such a technology would, for example, aid in the development of emerging therapies designed to halt or slow the immune attack on the pancreas or to restore insulin production. Currently, clinical trials of these rely on periodic laboratory tests that may miss short-term improvements or fail to capture the full effects of treatment. Continuous C-peptide monitoring, in contrast, would provide a sensitive and immediate measure of whether a therapy is working to restore endogenous insulin production (even against a background of ongoing insulin treatment), potentially reducing trial duration and accelerating the development of new treatments. Such a technology would also aid in the day-to-day management of diabetes by enabling real-time insights into endogenous insulin secretion, which could help explain why insulin needs vary from one day to the next and why glucose responses differ between individuals. Understanding when and how much insulin the body is still producing could support more precise insulin dosing strategies and reduce the risk of both high and low blood glucose levels.
More broadly, this project addresses a fundamental limitation in Type 1 diabetes care: the inability to observe pancreatic function directly and continuously. By enabling ongoing measurement of C-peptide in a wearable, minimally invasive format, this work has the potential to redefine how disease progression is monitored, how treatments are evaluated, and how care is personalized. Ultimately, the successful development of this technology could help shift Type 1 diabetes management from reactive glucose control toward proactive preservation and understanding of pancreatic function.